$1.60
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 154 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Key stats
Open
$1.64
Volume
164.07K
Market cap
$168.97M
Prev. close
$1.60
Impl / hst vl
-
Open interest
$0.00
$1.58
Day’s Range
$1.65
$1.26
52W Range
$5.39
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
7.10
P/B
1.68
Current ratio
2.38
Debt / Equity
0.72
ROE
-175.29%
Gross margin
59.73%
Income growth
106.75%
FCF growth
-19.85
Analysts estimates
Consensus rating
Buy
The average rating from top 7 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.15
The top 6 analysts forecasts that 12-month price may increase by 284.45%, with a low of $2.85 and a high of $9.82
$2.85
Low
$6.15
Avg
$9.82
High
Current price
Earnings
Q2 ‘26 revenue
$8.96M
Q2 ‘26 net income
-$38.49M
Revenue
Net income
Previous EPS
-$0.43
Estimate EPS
-$0.46
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply